Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ArgoMed Seeks Partner To Distribute Low-Cost BPH Treatment Device

This article was originally published in The Gray Sheet

Executive Summary

ArgoMed is planning to put its Thermoflex system for treatment of benign prostatic hyperplasia in the hands of a distribution partner capable of clearing a path into an already crowded market.

You may also be interested in...



ArgoMed

Convertible line of credit supplied via strategic alliance with Quintiles Transnational will be used to establish a sales force for a full-scale U.S. launch of ArgoMed's Thermoflex system for benign prostatic hyperplasia, ArgoMed announces May 2. The heated water therapy system gained 510(k) clearance in August 1999, but a full-scale launch was delayed pending suitable distribution arrangements (1"The Gray Sheet" Oct. 11, 1999, p. 20). A separate agreement with Timm Medical Technologies, announced May 3, will provide exclusive North American distribution rights for direct marketing to urologists offices

ArgoMed

Convertible line of credit supplied via strategic alliance with Quintiles Transnational will be used to establish a sales force for a full-scale U.S. launch of ArgoMed's Thermoflex system for benign prostatic hyperplasia, ArgoMed announces May 2. The heated water therapy system gained 510(k) clearance in August 1999, but a full-scale launch was delayed pending suitable distribution arrangements (1"The Gray Sheet" Oct. 11, 1999, p. 20). A separate agreement with Timm Medical Technologies, announced May 3, will provide exclusive North American distribution rights for direct marketing to urologists offices

BPH Treatment Devices To Be Reimbursed By HCFA At Approximately $1,875

EDAP expects that the lower cost of its Prostatron microwave-based system for treating benign prostatic hyperplasia will make the product more attractive than competing devices now that therapy has been assigned an ambulatory payment classification (APC) code with a set reimbursement level.

Related Content

UsernamePublicRestriction

Register

PS100968

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel